Financed Research Projects
100% of funds collected are allocated to paediatric cancer research projects meticulously selected by the Kriibskrank Kanner Foundation.
In fact, the "Fight Kids Cancer" initiative annually launches an international call for projects aimed at all European researchers working on pediatric cancers. Our common goal is to accelerate the development of more effective treatments to save more lives of children with cancer.
Meeting the strict criteria of innovation, international collaboration and significant impact on young patients, all projects are analyzed and ranked according to criteria of excellence by a panel of independent international experts. The best projects are selected and funded and here is the selection for 2021:
REGO-INTER-EWING program
This clinical trial aims to study the effectiveness of a new drug - regorafenib - in combination with traditional chemotherapy, for children with multimetastatic Ewing's sarcoma at diagnosis, in order to improve their prognosis which today is very poor in the event of a relapse.
GLO-BNHL program
This program will create a unique global platform for early clinical trials on relapsing and refractory pediatric non-Hodgkin B-cell lymphomas (LNHB), in order to rapidly identify and make available the most promising new treatments for children with this type of cancer with a poor prognosis.
In partnership with the European consortium ITCC (Innovative Therapies for Children with Cancer), the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the Children’s Oncology Group (COG) in the United States.
COMBALK program
The objective of this program is to identify new treatments for children with high-risk neuroblastoma and for whom Lorlatinib, used as a first-line treatment in cases of ALK genetic alteration, does not work (12 to 15% of patients).
CARBEMED program
This program offers a new treatment strategy for medulloblastoma that combines a new drug and a cellular immunotherapy treatment called CAR-T cells. The aim is to counter a major resistance mechanism in medulloblastoma and improve treatment efficacy without the side effects of current treatments.
BEACON BIO program
This international collaborative program aims to find new therapeutic approaches to treat high-risk neuroblastomas. More than one in two patients relapse after first-line treatments; it is therefore necessary to develop more effective combination therapies thanks to a better knowledge of tumor biology and by identifying groups of patients according to their molecular specificities.